Clinical Trials Using Saponin-based Immunoadjuvant OBI-821
Clinical trials are research studies that involve people. The clinical trials on this list are studying Saponin-based Immunoadjuvant OBI-821. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
Study of Adagloxad Simolenin (OBI-822) and OBI-821 Versus Placebo Treatment for High Risk Early Stage Triple Negative Breast Cancer Patients (TNBC) Following Neoadjuvant or Adjuvant Chemotherapy.
This is a Phase III, randomized, double-blind, placebo controlled, study to prospectively evaluate the efficacy and safety of adagloxad simolenin (OBI 822) / OBI-821 treatment, compared to placebo, in patients with early stage TNBC at high risk for recurrence.
Location: 3 locations
OPT-821 with Vaccine Therapy and Beta-Glucan in Treating Younger Patients with High-Risk Neuroblastoma
This randomized phase I / II trial studies the side effects and best dose of OPT-821 (saponin-based immunoadjuvant OBI-821) with vaccine therapy when given together with beta-glucan and how well the regimen works in treating younger patients with neuroblastoma that is likely to recur (come back), or spread (high-risk). Biological therapies, such as OPT-821 and beta-glucan, may stimulate the immune system in different ways and stop tumor cells from growing. Vaccines may help the body build an effective immune response to kill tumor cells. Giving OPT-821 with vaccine therapy together with beta-glucan may be an effective treatment for high-risk neuroblastoma.
Location: Memorial Sloan Kettering Cancer Center, New York, New York